Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches
Business Wire India Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs. Abexxa’s focus is on the development of specific antibodies to…